{"url_path":"/sec/xfor/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1501697/0001501697-26-000051-index.html","accession_number":"0001501697-26-000051","cik":"0001501697","ticker":"XFOR","issuer_name":"X4 Pharmaceuticals, Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501697/0001501697-26-000051-index.html","primary_entity_key":"0001501697","primary_entity_name":"X4 Pharmaceuticals, Inc"},"word_count":74,"has_tables":true,"body_markdown":"Item 9.01Financial Statements and Exhibits.\n\nExhibit No.Description\n\n10.1\n[Second Amended and Restated 2017 Equity Incentive Plan](ex-101secondamendedandrest.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nX4 PHARMACEUTICALS, INC.\n\nDate: May 13, 2026By:/s/ David Kirske\n\nName:David Kirske\n\nTitle:Chief Financial Officer and Treasurer"}